<DOC>
	<DOC>NCT01982461</DOC>
	<brief_summary>The objective of this trial is to assess the efficacy of reducing plasma low-density lipoprotein(LDL) cholesterol and safety in two different brand drugs, Roty F.C. Tablets 10mg and Crestor 10mg F.C. Tablets in hypercholesterolemia population.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male or female aged 20 to 85; LDL C between 130 mg/dL and 250 mg/dL; TG &lt; 400 mg/dL; Who without use of any statin within 2 week prior to the trial; Informed consent given. Known hypersensitivity or history of SAE with another HMGCoA reductase inhibitor, in particular any history of myopathy; Active liver disease/severe hepatic impairment(ChildPugh C,ALT2Ã—ULN); Treatment with Cyclosporin or any disallowed drug; Patients with unstable angina pectoris; Pregnant, lactating women; Patients who have severe medical condition(s) that in the view of the Investigator prohibits participation in the trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>